The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
Fournier
A
A
Oprisiu
R
R
Albu
A T
AT
Dungaciu
M
M
El Esper
N
N
Mornière
P
P
D000085:Acetates / Q000627:therapeutic use*; D002112:Calcifediol / Q000097:blood; D002114:Calcinosis / Q000517:prevention & control; D002118:Calcium / Q000627:therapeutic use*; D017610:Calcium Compounds; D002214:Capsules; D002318:Cardiovascular Diseases / Q000517:prevention & control; D018592:Cross-Over Studies; D006801:Humans; D006934:Hypercalcemia / Q000517:prevention & control; D006962:Hyperparathyroidism, Secondary / Q000517:prevention & control; D010710:Phosphates / Q000037:antagonists & inhibitors* / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000627:therapeutic use*; D006435:Renal Dialysis; D000069603:Sevelamer
D000085:Acetates; D017610:Calcium Compounds; D002214:Capsules; D010710:Phosphates; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D002112:Calcifediol; D002118:Calcium; C120662:calcium acetate